Related Experiment Video
Updated: Aug 9, 2026
10:38
Evaluating the Differentiation Capacity of Mouse Prostate Epithelial Cells Using Organoid Culture
Published on: November 22, 2019
Decoding benign prostatic hyperplasia at single-cell resolution: heterogeneity, inflammation, and beyond
Yihao Liao1, Siyuan Jiang2, Haohan Wang1
1Department of Urology, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People's Hospital, Yichang, China.
Frontiers in Immunology
|August 8, 2026
Summary
Single-cell RNA sequencing reveals benign prostatic hyperplasia (BPH) is a complex disease driven by cell-immune interactions, not just hormones. This approach identifies new therapeutic targets beyond the androgen axis for better BPH treatment.
Area of Science:
- Urology
- Immunology
- Genomics
Background:
- Benign prostatic hyperplasia (BPH) is a common age-related condition often treated with hormonal therapies.
- Limited efficacy of current treatments necessitates exploring alternative BPH mechanisms.
- Single-cell RNA sequencing (scRNA-seq) offers high-resolution insights into prostate cellular heterogeneity.
Purpose of the Study:
- To review advancements in applying scRNA-seq to BPH research.
- To highlight the shift towards understanding BPH as a complex, heterogeneous disease.
- To identify novel therapeutic targets and biomarkers for BPH.
Main Methods:
- Review of recent studies utilizing scRNA-seq in BPH research.
- Analysis of cellular heterogeneity and microenvironmental dynamics in the prostate.
- Identification of specific cellular subsets and immune interactions in BPH pathogenesis.
Main Results:
- scRNA-seq reveals distinct cellular subsets in BPH transition zones, including novel basal epithelial and activated fibroblast subtypes.
- Chronic inflammation, immune cell infiltration, and SASP are identified as key drivers of BPH progression.
- New therapeutic targets, including the CXCL13/CD4+ T cell axis and granzyme K pathways, are identified, offering alternatives to androgen-based treatments.
Conclusions:
- scRNA-seq is transforming the understanding of BPH pathophysiology from a hormone-centric to a multifaceted cell-immune interaction model.
- This technology facilitates the identification of novel, non-androgenic therapeutic strategies and biomarkers.
- Future integration with spatial multi-omics will enable precision medicine approaches for BPH treatment.
